Sichuan Kelun-Biotech’s Sac-TMT Approved for New Lung Cancer Indication

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has shared an announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its core product, sacituzumab tirumotecan (sac-TMT), has been approved by the National Medical Products Administration for marketing as a treatment for adult patients with EGFR mutant-positive non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR-TKI therapy and platinum-based chemotherapy. This approval marks the first global marketing of a TROP2 ADC drug for lung cancer, highlighting sac-TMT’s significant improvement in survival benefits compared to existing treatments, and enhancing the company’s positioning in the oncology market.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of antibody-drug conjugates (ADCs) for treating advanced solid tumors such as non-small cell lung cancer (NSCLC), breast cancer, and other cancers. The company holds proprietary intellectual property rights for its core product, sacituzumab tirumotecan (sac-TMT), which targets TROP2 on tumor cells.

YTD Price Performance: 51.62%

Average Trading Volume: 326,754

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$55.18B

Learn more about 6990 stock on TipRanks’ Stock Analysis page.